News & Views | Telix Pharmaceuticals Limited

Telix Pharmaceuticals launches information site on illumet™ prostate cancer imaging product

Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical use for prostate cancer.

Strategy Update – Acceleration of Prostate Cancer Therapy Program

Telix Pharmaceuticals Limited today announced a strategy update for the TLX591 (prostate therapy) program.

Telix Pharmaceuticals & Radboud University Medical Centre Conclude Clinical Collaboration Agreement

Telix Pharmaceuticals has today announced a clinical collaboration with Radboud University Medical Center.

Telix Pharmaceuticals and Memorial Sloan Kettering Cancer Center Announce Renal Cancer Collaboration

Telix has today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK)

Telix Pharmaceuticals and AMNI Partner for Prostate Cancer Imaging

Telix Pharmaceuticals is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA (ANMI).

Telix and University of Melbourne Establish Cancer Translational Research Partnership

Telix is pleased to announce that it has entered into a technology licensing agreement and a research collaboration agreement with the University of Melbourne.